Sang-Cheol Bae

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9411333/publications.pdf

Version: 2024-02-01

250 papers	15,701 citations	43973 48 h-index	20307 116 g-index
254 all docs	254 docs citations	254 times ranked	19022 citing authors

#	Article	IF	Citations
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
2	Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 2014, 506, 376-381.	13.7	1,974
3	Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nature Genetics, 2012, 44, 291-296.	9.4	768
4	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 382, 211-221.	13.9	725
5	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.5	391
6	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	0.9	370
7	Systematic review of the epidemiology of systemic lupus erythematosus in the Asiaâ€Pacific region: Prevalence, incidence, clinical features, and mortality. Arthritis Care and Research, 2012, 64, 159-168.	1.5	260
8	Cancer risk in systemic lupus: An updated international multi-centre cohort study. Journal of Autoimmunity, 2013, 42, 130-135.	3.0	249
9	High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry. Nature Genetics, 2016, 48, 323-330.	9.4	219
10	A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Annals of the Rheumatic Diseases, 2018, 77, 355-363.	0.5	196
11	A functional haplotype of thePADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis and Rheumatism, 2006, 54, 90-96.	6.7	144
12	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.5	143
13	A missense variant in NCF1 is associated with susceptibility to multiple autoimmune diseases. Nature Genetics, 2017, 49, 433-437.	9.4	143
14	Genomeâ€Wide Association Study in an Amerindian Ancestry Population Reveals Novel Systemic Lupus Erythematosus Risk Loci and the Role of European Admixture. Arthritis and Rheumatology, 2016, 68, 932-943.	2.9	138
15	Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Human Molecular Genetics, 2014, 23, 6916-6926.	1.4	135
16	Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. Journal of Rheumatology, 2007, 34, 706-11.	1.0	131
17	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the Rheumatic Diseases, 2021, 80, 848-858.	0.5	123
18	Genomeâ€wide association study of rheumatoid arthritis in Koreans: Populationâ€specific loci as well as overlap with European susceptibility loci. Arthritis and Rheumatism, 2011, 63, 884-893.	6.7	121

#	Article	IF	Citations
19	IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis. Arthritis Research and Therapy, 2018, 20, 115.	1.6	116
20	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Annals of the Rheumatic Diseases, 2014, 73, 138-142.	0.5	115
21	Genome-wide pathway analysis of genome-wide association studies on systemic lupus erythematosus and rheumatoid arthritis. Molecular Biology Reports, 2012, 39, 10627-10635.	1.0	114
22	Genetic risk factors for rheumatoid arthritis differ in caucasian and Korean populations. Arthritis and Rheumatism, 2009, 60, 364-371.	6.7	109
23	Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 632-640.	0.5	103
24	Update on the genetic architecture of rheumatoid arthritis. Nature Reviews Rheumatology, 2017, 13, 13-24.	3.5	102
25	High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. Annals of the Rheumatic Diseases, 2015, 74, e13-e13.	0.5	100
26	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	2.9	98
27	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	1.1	97
28	Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci. Annals of the Rheumatic Diseases, 2021, 80, 558-565.	0.5	93
29	Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. International Journal of Rheumatic Diseases, 2013, 16, 527-531.	0.9	90
30	Identification of a Systemic Lupus Erythematosus Risk Locus Spanning ATG16L2, FCHSD2, and P2RY2 in Koreans. Arthritis and Rheumatology, 2016, 68, 1197-1209.	2.9	89
31	Effects of Antioxidant Supplements Intervention on the Level of Plasma Inflammatory Molecules and Disease Severity of Rheumatoid Arthritis Patients. Journal of the American College of Nutrition, 2009, 28, 56-62.	1.1	86
32	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84
33	The HLA-DRÎ²1 amino acid positions 11â€“13â€“26 explain the majority of SLEâ€“MHC associations. Nature Communications, 2014, 5, 5902.	5.8	80
34	Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity. Arthritis Research and Therapy, 2016, 18, 1.	1.6	80
35	Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database. Rheumatology International, 2013, 33, 2985-2992.	1.5	78
36	Inadequate Antioxidant Nutrient Intake and Altered Plasma Antioxidant Status of Rheumatoid Arthritis Patients. Journal of the American College of Nutrition, 2003, 22, 311-315.	1.1	76

#	Article	IF	Citations
37	The IRF5â€“TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Human Molecular Genetics, 2015, 24, 582-596.	1.4	74
38	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.5	70
39	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70
40	Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis. American Journal of Human Genetics, 2016, 99, 366-374.	2.6	68
41	Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. Human Molecular Genetics, 2014, 23, 1656-1668.	1.4	67
42	Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis. Clinical and Experimental Rheumatology, 2016, 34, 827-833.	0.4	66
43	Prevalence and incidence of rheumatoid arthritis in South Korea. Rheumatology International, 2013, 33, 1525-1532.	1.5	62
44	Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A metaâ€analysis. International Journal of Rheumatic Diseases, 2018, 21, 664-672.	0.9	60
45	Two Functional Lupus-Associated BLK Promoter Variants Control Cell-Type- and Developmental-Stage-Specific Transcription. American Journal of Human Genetics, 2014, 94, 586-598.	2.6	59
46	Interactions Between Amino Acidâ€“Defined Major Histocompatibility Complex Class II Variants and Smoking in Seropositive Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2611-2623.	2.9	58
47	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	1.5	55
48	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	2.9	55
49	Korean Observational Study Network for Arthritis (KORONA): Establishment of a Prospective Multicenter Cohort for Rheumatoid Arthritis in South Korea. Seminars in Arthritis and Rheumatism, 2012, 41, 745-751.	1.6	54
50	Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization. Rheumatology International, 2018, 38, 649-656.	1.5	48
51	Confirmation of five novel susceptibility loci for Systemic Lupus Erythematosus (SLE) and integrated network analysis of 82 SLE susceptibility loci. Human Molecular Genetics, 2017, 26, ddx026.	1.4	47
52	Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis. Rheumatology International, 2017, 37, 1735-1745.	1.5	43
53	The Prevalence and Trend of Arthritis in Korea: Results from Korea National Health and Nutrition Examination Surveys. The Journal of the Korean Rheumatism Association, 2008, 15, 11.	0.1	42
54	Associations between TNFAIP3 gene polymorphisms and rheumatoid arthritis: a meta-analysis. Inflammation Research, 2012, 61, 635-641.	1.6	42

#	Article	IF	Citations
55	MiRâ€146a levels in rheumatoid arthritis and their correlation with disease activity: a metaâ€analysis. International Journal of Rheumatic Diseases, 2018, 21, 1335-1342.	0.9	42
56	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.5	42
57	Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network metaâ€analysis of randomized controlled trials. International Journal of Rheumatic Diseases, 2016, 19, 1103-1111.	0.9	41
58	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	2.9	40
59	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.5	40
60	Differences in Clinical Features and Mortality between Childhood-onset and Adult-onset Systemic Lupus Erythematosus: A Prospective Single-center Study. Journal of Rheumatology, 2016, 43, 1490-1497.	1.0	39
61	A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Annals of the Rheumatic Diseases, 2017, 76, 65-71.	0.5	39
62	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	2.9	39
63	Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskeletal Disorders, 2013, 14, 13.	0.8	38
64	The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis. BMC Musculoskeletal Disorders, 2016, 17, 98.	0.8	38
65	Prevalence and incidence of systemic lupus erythematosus in South Korea. Rheumatology International, 2014, 34, 909-917.	1.5	37
66	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	0.9	37
67	Vitamin D level and risk of systemic lupus erythematosus and rheumatoid arthritis: a Mendelian randomization. Clinical Rheumatology, 2018, 37, 2415-2421.	1.0	37
68	Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. American Journal of Human Genetics, 2015, 96, 731-739.	2.6	36
69	Clinical characteristics and outcomes of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2017, 46, 782-787.	1.6	36
70	Correlation between circulating VEGF levels and disease activity in rheumatoid arthritis: aÂmeta-analysis. Zeitschrift Fur Rheumatologie, 2018, 77, 240-248.	0.5	36
71	Amino acid signatures of HLA Class-I and II molecules are strongly associated with SLE susceptibility and autoantibody production in Eastern Asians. PLoS Genetics, 2019, 15, e1008092.	1.5	36
72	Incidence and risk factors of fractures in patients with rheumatoid arthritis: an Asian prospective cohort study. Rheumatology International, 2016, 36, 1205-1214.	1.5	35

#	Article	IF	Citations
73	Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Rheumatology International, 2016, 36, 1591-1599.	1.5	35
74	CCL2 deficient mesenchymal stem cells fail to establish long-lasting contact with T cells and no longer ameliorate lupus symptoms. Scientific Reports, 2017, 7, 41258.	1.6	35
75	A plausibly causal functional lupus-associated risk variant in the STAT1â€“STAT4 locus. Human Molecular Genetics, 2018, 27, 2392-2404.	1.4	34
76	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	1.0	34
77	Mortality and Incidence of Malignancy in Korean Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 226-232.	1.0	32
78	Associations between circulating IL-17 levels and rheumatoid arthritis and between IL-17 gene polymorphisms and disease susceptibility: a meta-analysis. Postgraduate Medical Journal, 2017, 93, 465-471.	0.9	32
79	Causal association between body mass index and risk of rheumatoid arthritis: A Mendelian randomization study. European Journal of Clinical Investigation, 2019, 49, e13076.	1.7	32
80	Factors Influencing Discrepancies Between the QuantiFERON-TB Gold in Tube Test and the Tuberculin Skin Test in Korean Patients with Rheumatic Diseases. Seminars in Arthritis and Rheumatism, 2013, 42, 424-432.	1.6	31
81	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Annals of the Rheumatic Diseases, 2021, 80, 1.1-2.	0.5	31
82	Diagnostic accuracy of lung ultrasound for interstitial lung disease in patients with connective tissue diseases: a meta-analysis. Clinical and Experimental Rheumatology, 2016, 34, 11-6.	0.4	31
83	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	1.1	31
84	Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. Postgraduate Medicine, 2017, 129, 531-537.	0.9	30
85	Association analyses of DNA methyltransferase-1 (DNMT1) polymorphisms with systemic lupus erythematosus. Journal of Human Genetics, 2004, 49, 642-646.	1.1	29
86	Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskeletal Disorders, 2016, 17, 333.	0.8	28
87	Associations between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis, and betweenMIFgene polymorphisms and disease susceptibility: a meta-analysis. Postgraduate Medical Journal, 2018, 94, 109-115.	0.9	28
88	Construction and Application of a Korean Reference Panel for Imputing Classical Alleles and Amino Acids of Human Leukocyte Antigen Genes. PLoS ONE, 2014, 9, e112546.	1.1	27
89	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 393-396.	1.0	27
90	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	3.0	27

#	Article	IF	Citations
91	Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials. Korean Journal of Internal Medicine, 2014, 29, 656.	0.7	27
92	Recent advances in understanding the genetic basis of systemic lupus erythematosus. Seminars in Immunopathology, 2022, 44, 29-46.	2.8	27
93	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	2.9	26
94	Genome-wide association study in a Korean population identifies six novel susceptibility loci for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 1438-1445.	0.5	26
95	Lupus risk variants in the PXK locus alter B-cell receptor internalization. Frontiers in Genetics, 2015, 5, 450.	1.1	25
96	Genetic variants in systemic lupus erythematosus susceptibility loci, XKR6 and GLT1D1 are associated with childhood-onset SLE in a Korean cohort. Scientific Reports, 2018, 8, 9962.	1.6	25
97	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	2.9	25
98	Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activityâ€"results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology, 2016, 26, 651-661.	0.9	24
99	Development of the Asia Pacific Lupus Collaboration cohort. International Journal of Rheumatic Diseases, 2019, 22, 425-433.	0.9	24
100	An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Seminars in Arthritis and Rheumatism, 2020, 50, 526-533.	1.6	24
101	Prevalence and possible causes of hypouricemia at a tertiary care hospital. Korean Journal of Internal Medicine, 2016, 31, 971-976.	0.7	23
102	Association-heterogeneity mapping identifies an Asian-specific association of the GTF2I locus with rheumatoid arthritis. Scientific Reports, 2016, 6, 27563.	1.6	23
103	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	1.5	23
104	Excess mortality persists in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2021, 24, 364-372.	0.9	23
105	Association between Vitamin D level and/or deficiency, and systemic lupus erythematosus: a meta-analysis. Cellular and Molecular Biology, 2018, 64, 7-13.	0.3	23
106	Association of genetic polymorphisms in CD40 with susceptibility to SLE in the Korean population. Rheumatology, 2013, 52, 623-630.	0.9	22
107	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	1.5	22
108	An HLA-C amino-acid variant in addition to HLA-B*27 confers risk for ankylosing spondylitis in the Korean population. Arthritis Research and Therapy, 2015, 17, 342.	1.6	21

#	Article	IF	Citations
109	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	1.5	21
110	Glucocorticoids Are Associated with an Increased Risk for Vertebral Fracture in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2018, 45, 612-620.	1.0	20
111	Imputing Variants in HLA-DR Beta Genes Reveals That HLA-DRB1 Is Solely Associated with Rheumatoid Arthritis and Systemic Lupus Erythematosus. PLoS ONE, 2016, 11, e0150283.	1.1	20
112	Factors Associated with the Use of Complementary and Alternative Medicine for Korean Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 2075-2081.	1.0	19
113	The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs. Arthritis Research and Therapy, 2017, 19, 277.	1.6	19
114	Factors associated with time to diagnosis from symptom onset in patients with early rheumatoid arthritis. Korean Journal of Internal Medicine, 2019, 34, 910-916.	0.7	19
115	Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus. Autoimmune Diseases, 2012, 2012, 1-6.	2.7	18
116	Clinical validation of surface-enhanced Raman scattering-based immunoassays in the early diagnosis of rheumatoid arthritis. Analytical and Bioanalytical Chemistry, 2015, 407, 8353-8362.	1.9	18
117	Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data. Rheumatology International, 2016, 36, 505-513.	1.5	18
118	Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clinical Rheumatology, 2018, 37, 1471-1479.	1.0	18
119	SERS-based immunoassay of anti-cyclic citrullinated peptide for early diagnosis of rheumatoid arthritis. RSC Advances, 2014, 4, 32924-32927.	1.7	17
120	Brief Report: Influence of HLAâ€“DRB1 Susceptibility Alleles on the Clinical Subphenotypes of Systemic Lupus Erythematosus in Koreans. Arthritis and Rheumatology, 2016, 68, 1190-1196.	2.9	17
121	Direct medical costs and their predictors in South Korean patients with systemic lupus erythematosus. Rheumatology International, 2015, 35, 1809-1815.	1.5	17
122	Coffee consumption and the risk of rheumatoid arthritis and systemic lupus erythematosus: a Mendelian randomization study. Clinical Rheumatology, 2018, 37, 2875-2879.	1.0	17
123	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	2.9	17
124	Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open, 2021, 7, e001629.	1.8	17
125	â€˜Not at targetâ€™: prevalence and consequences of inadequate disease control in systemic lupus erythematosusâ€”a multinational observational cohort study. Arthritis Research and Therapy, 2022, 24, 70.	1.6	17
126	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	2.2	17

#	Article	IF	Citations
127	The Role of Bone Scintigraphy in the Diagnosis of Rheumatoid Arthritis According to the 2010 ACR/EULAR Classification Criteria. Journal of Korean Medical Science, 2014, 29, 204.	1.1	16
128	Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production. Annals of the Rheumatic Diseases, 2016, 75, 2007-2013.	0.5	16
129	What factors affect discordance between physicians and patients in the global assessment of disease activity in rheumatoid arthritis?. Modern Rheumatology, 2017, 27, 35-41.	0.9	16
130	Development of a Paper-Based Viscometer for Blood Plasma Using Colorimetric Analysis. Analytical Chemistry, 2019, 91, 4868-4875.	3.2	16
131	Response to Intravenous Cyclophosphamide Treatment for Lupus Nephritis Associated with Polymorphisms in the FCGR2B-FCRLA Locus. Journal of Rheumatology, 2016, 43, 1045-1049.	1.0	15
132	Impact of early diagnosis on functional disability in rheumatoid arthritis. Korean Journal of Internal Medicine, 2017, 32, 738-746.	0.7	15
133	LB0001â€…EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS. , 2019, , .		15
134	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. Lupus Science and Medicine, 2019, 6, e000342.	1.1	15
135	Synergistic activation of NF-Î²B by TNFAIP3 (A20) reduction and UBE2L3 (UBCH7) augment that synergistically elevate lupus risk. Arthritis Research and Therapy, 2020, 22, 93.	1.6	15
136	Cross-cultural adaptation and validation of the Korean fibromyalgia impact questionnaire in women patients with fibromyalgia for clinical research. Quality of Life Research, 2004, 13, 857-861.	1.5	14
137	Association between FCGR3B copy number variations and susceptibility to autoimmune diseases: a meta-analysis. Inflammation Research, 2015, 64, 983-991.	1.6	14
138	Association between Functional CYP2D6 Polymorphisms and Susceptibility to Autoimmune Diseases: A Meta-Analysis. Immunological Investigations, 2017, 46, 109-122.	1.0	14
139	Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil. International Journal of Rheumatic Diseases, 2018, 21, 1031-1039.	0.9	14
140	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology, 2021, 60, 4737-4747.	0.9	14
141	Human SLE variant NCF1-R90H promotes kidney damage and murine lupus through enhanced Tfh2 responses induced by defective efferocytosis of macrophages. Annals of the Rheumatic Diseases, 2022, 81, 255-267.	0.5	14
142	Mesenchymal Stem Cells Ameliorate Renal Inflammation in Adriamycin-induced Nephropathy. Immune Network, 2019, 19, e36.	1.6	14
143	Vitamin D receptor FokI, TaqI, and ApaI polymorphisms and susceptibility to systemic lupus erythematosus: an updated meta-analysis. Clinical Rheumatology, 2018, 37, 1529-1537.	1.0	13
144	Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2018, 47, 501-506.	1.6	13

#	Article	IF	Citations
145	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	1.5	13
146	Mortality in Korean Patients With Rheumatoid Arthritis. Journal of Rheumatic Diseases, 2021, 28, 113-118.	0.4	13
147	Risk Factors of Outcomes of COVID-19 Patients in Korea: Focus on Early Symptoms. Journal of Korean Medical Science, 2021, 36, e132.	1.1	13
148	DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice. Journal of Immunology Research, 2015, 2015, 1-15.	0.9	12
149	Effect of a Combination of Prednisone or Mycophenolate Mofetil and Mesenchymal Stem Cells on Lupus Symptoms in MRL.Fas^{lpr} Mice. Stem Cells International, 2018, 2018, 1-10.	1.2	12
150	Prevalence and predictors for sustained remission in rheumatoid arthritis. PLoS ONE, 2019, 14, e0214981.	1.1	12
151	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.5	12
152	COVIDâ€19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. International Journal of Rheumatic Diseases, 2020, 23, 1255-1257.	0.9	12
153	Genetic variants shape rheumatoid arthritis-specific transcriptomic features in CD4⁺ T cells through differential DNA methylation, explaining a substantial proportion of heritability. Annals of the Rheumatic Diseases, 2021, 80, 876-883.	0.5	12
154	The Current Status of Surveys on Prevalence of Rheumatic Diseases in Korea. The Journal of the Korean Rheumatism Association, 2010, 17, 1.	0.1	11
155	Validity and role of vertebral fracture assessment in detecting prevalent vertebral fracture in patients with rheumatoid arthritis. Joint Bone Spine, 2014, 81, 149-153.	0.8	11
156	Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment. Seminars in Arthritis and Rheumatism, 2017, 47, 102-107.	1.6	11
157	Biological function integrated prediction of severe radiographic progression in rheumatoid arthritis: a nested case control study. Arthritis Research and Therapy, 2017, 19, 244.	1.6	11
158	Increased risk of opportunistic infection in early rheumatoid arthritis. International Journal of Rheumatic Diseases, 2019, 22, 1239-1246.	0.9	11
159	Effect of Human Mesenchymal Stem Cells on Xenogeneic T and B Cells Isolated from Lupus-Prone MRL.Faslpr Mice. Stem Cells International, 2020, 2020, 1-10.	1.2	11
160	Lupus Susceptibility Region Containing CDKN1B rs34330 Mechanistically Influences Expression and Function of Multiple Target Genes, Also Linked to Proliferation and Apoptosis. Arthritis and Rheumatology, 2021, 73, 2303-2313.	2.9	11
161	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. Clinical Immunology, 2015, 161, 157-162.	1.4	10
162	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Annals of the Rheumatic Diseases, 2016, 75, 242-252.	0.5	10

#	Article	IF	Citations
163	Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab. Rheumatology International, 2017, 37, 1007-1014.	1.5	10
164	Predictors of severe radiographic progression in patients with early rheumatoid arthritis: A Prospective observational cohort study. International Journal of Rheumatic Diseases, 2017, 20, 1437-1446.	0.9	10
165	Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clinical Rheumatology, 2018, 37, 1199-1205.	1.0	10
166	Causal relationship between years of education and the occurrence of rheumatoid arthritis. Postgraduate Medical Journal, 2019, 95, 378-381.	0.9	10
167	Phorbol ester activates human mesenchymal stem cells to inhibit B cells and ameliorate lupus symptoms in MRL.Fas^{lpr} mice. Theranostics, 2020, 10, 10186-10199.	4.6	10
168	Characteristics of Korean Patients with RA: A Single Center Cohort Study. The Journal of the Korean Rheumatism Association, 2009, 16, 204.	0.1	10
169	Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). Modern Rheumatology, 2022, 32, 263-272.	0.9	10
170	Association of Complement Receptor 2 Gene Polymorphisms with Susceptibility to Osteonecrosis of the Femoral Head in Systemic Lupus Erythematosus. BioMed Research International, 2016, 2016, 1-6.	0.9	9
171	ABCG2Polymorphism Is Associated with Hyperuricemia in a Study of a Community-Based Korean Cohort. Journal of Korean Medical Science, 2017, 32, 1451.	1.1	9
172	Associations between paraoxonase 1 (PON1) polymorphisms and susceptibility and PON1 activity in rheumatoid arthritis patients, and comparison of PON1 activity in patients and controls: a meta-analysis. Clinical Rheumatology, 2019, 38, 2141-2149.	1.0	9
173	Understanding HLA associations from SNP summary association statistics. Scientific Reports, 2019, 9, 1337.	1.6	9
174	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	1.5	9
175	Association of HLA-G polymorphisms with systemic lupus erythematosus and correlation between soluble HLAâ€‘G levels and the disease: aÂmeta-analysis. Zeitschrift Fur Rheumatologie, 2021, 80, 96-102.	0.5	9
176	Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study. Clinical and Experimental Rheumatology, 2019, 37, 89-96.	0.4	9
177	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.5	9
178	Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study. Annals of the Rheumatic Diseases, 2022, 81, 1273-1280.	0.5	9
179	Water Intoxication Following Low-Dose Intravenous Cyclophosphamide. Electrolyte and Blood Pressure, 2007, 5, 50.	0.6	8
180	Clinical characteristics of multifocal osteonecrosis in Korean patients with rheumatic disease. International Journal of Rheumatic Diseases, 2018, 21, 1301-1308.	0.9	8

#	Article	IF	Citations
181	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	0.9	8
182	Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested caseâ€“control study. RMD Open, 2022, 8, e001892.	1.8	8
183	Meta-analysis of gene expression profiles of peripheral blood cells in systemic lupus erythematosus. Cellular and Molecular Biology, 2018, 64, 40-49.	0.3	8
184	Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis. Journal of Korean Medical Science, 2016, 31, 1907.	1.1	7
185	Comparative efficacy and safety of biosimilarâ€infliximab and originatorâ€infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a metaâ€analysis of randomized controlled trials. International Journal of Rheumatic Diseases, 2018, 21, 922-929.	0.9	7
186	TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis. Zeitschrift Fur Rheumatologie, 2018, 77, 824-832.	0.5	7
187	Association of CD8⁺ Tâ€cells with bone erosion in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2018, 21, 440-446.	0.9	7
188	Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study. Journal of Korean Medical Science, 2021, 36, e70.	1.1	7
189	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. Lupus Science and Medicine, 2021, 8, e000433.	1.1	7
190	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	2.9	7
191	Clinical and Genetic Risk Factors Associated With the Presence of Lupus Nephritis. Journal of Rheumatic Diseases, 2021, 28, 150-158.	0.4	7
192	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	1.5	7
193	The frequency of single nucleotide polymorphisms and their association with uric acid concentration based on data from genome-wide association studies in the Korean population. Rheumatology International, 2014, 34, 777-783.	1.5	6
194	Strategies for the safe use of non-steroidal anti-inflammatory drugs. Journal of the Korean Medical Association, 2018, 61, 367.	0.1	6
195	Association between CD40 polymorphisms and systemic lupus erythematosus and correlation between soluble CD40 and CD40 ligand levels in the disease: a meta-analysis. Lupus, 2019, 28, 1452-1459.	0.8	6
196	Identifying damage clusters in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2020, 23, 84-91.	0.9	6
197	Characteristics in Pediatric Patients with Coronavirus Disease 2019 in Korea. Journal of Korean Medical Science, 2021, 36, e148.	1.1	6
198	Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. Arthritis Care and Research, 2022, 74, 2033-2041.	1.5	6

#	Article	IF	Citations
199	The Influence of Vertebral Fracture on the Functional Disability of Patients with Rheumatoid Arthritis. Journal of Korean Medical Science, 2014, 29, 859.	1.1	5
200	Impact of Childbearing Decisions on Family Size of Korean Women with Systemic Lupus Erythematosus. Journal of Korean Medical Science, 2016, 31, 729.	1.1	5
201	Nonâ€aneurysmal subarachnoid hemorrhage in two patients with systemic lupus erythematosus: Case reports and literature review. International Journal of Rheumatic Diseases, 2018, 21, 761-766.	0.9	5
202	Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with diseaseâ€modifying antiâ€rheumatic drugs for at least 6 months. International Journal of Rheumatic Diseases, 2018, 21, 1001-1009.	0.9	5
203	Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea. Journal of Korean Medical Science, 2018, 33, e346.	1.1	5
204	Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?. Korean Journal of Internal Medicine, 2014, 29, 509.	0.7	5
205	Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis. Cellular and Molecular Biology, 2018, 64, 46-51.	0.3	5
206	Clinical experience with tumor necrosis factor blockers in Korean rheumatoid arthritis patients. APLAR Journal of Rheumatology, 2006, 9, 146-149.	0.2	4
207	Impact of Change in Reimbursement Guideline of Rheumatoid Arthritis on the Short Term Persistence of Tumor Necrosis Factor (TNF) Blockers. Journal of Rheumatic Diseases, 2011, 18, 283.	0.4	4
208	Improving Participation in Clinical Trials of Novel Therapies. Rheumatic Disease Clinics of North America, 2014, 40, 553-559.	0.8	4
209	Pharmacologic treatment of rheumatoid arthritis. Journal of the Korean Medical Association, 2017, 60, 156.	0.1	4
210	Comparative efficacy and tolerability of monotherapy with leflunomide or tacrolimus for the treatment of rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clinical Rheumatology, 2018, 37, 323-330.	1.0	4
211	Comparison of screening strategies for prevalent vertebral fractures in South Korea: vertebral fracture assessment vs. spine radiography. BMC Musculoskeletal Disorders, 2018, 19, 46.	0.8	4
212	Alleleâ€Specific Quantification of HLAâ€“DRB1 Transcripts Reveals Imbalanced Allelic Expression That Modifies the Amino Acid Effects in HLAâ€“DRÎ²1. Arthritis and Rheumatology, 2021, 73, 381-391.	2.9	4
213	Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies. Journal of Korean Medical Science, 2020, 35, e335.	1.1	4
214	Treatment Persistence with TNF Blocker in Korean Rheumatoid Arthritis Patients. Journal of Rheumatic Diseases, 2011, 18, 161.	0.4	3
215	Incidence of Tuberculosis in Rheumatoid Arthritis Patients Using Anti-Tumor Necrosis Factor Agents following Latent Tuberculosis Infection Screening Strategies. Journal of Rheumatic Diseases, 2015, 22, 223.	0.4	3
216	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	0.8	3

#	Article	IF	Citations
217	Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy. Korean Journal of Internal Medicine, 2018, 33, 1016-1024.	0.7	3
218	Predictive Factors for Renal Response in Lupus Nephritis: A Single-center Prospective Cohort Study. Journal of Rheumatic Diseases, 2022, 29, 223-231.	0.4	3
219	Safety and tolerability of bone marrowâ€“derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans. Lupus, 2022, 31, 1245-1253.	0.8	3
220	Association between the functional MHC2TA â^'168 A/G polymorphism and susceptibility to rheumatoid arthritis: a meta-analysis. Clinical Rheumatology, 2016, 35, 901-909.	1.0	2
221	Productivity Loss of Rheumatoid Arthritis Patients according to the Their Stages of the Disease Activity Score. Journal of Rheumatic Diseases, 2018, 25, 122.	0.4	2
222	Associations between paraoxonase-1 and systemic lupus erythematosus. Lupus, 2019, 28, 1571-1576.	0.8	2
223	Relationship between cerebral microbleeds and white matter MR hyperintensities in systemic lupus erythematosus: a retrospective observational study. Neuroradiology, 2019, 61, 265-274.	1.1	2
224	Fracture Risk and its Prevention Patterns in Korean Patients with Polymyalgia Rheumatica: a Retrospective Cohort Study. Journal of Korean Medical Science, 2021, 36, e263.	1.1	2
225	TNF Inhibitors and Uveitis in Ankylosing Spondylitis. The Journal of the Korean Rheumatism Association, 2009, 16, 48.	0.1	1
226	Rheumatoid arthritis: past, present and future. Journal of the Korean Medical Association, 2010, 53, 842.	0.1	1
227	Biologics use in sle in 23 centers â€“ data from the international registry for biologics in SLE. Annals of the Rheumatic Diseases, 2012, 71, A9.1-A9.	0.5	1
228	Diagnosis and Treatment of Lupus Nephritis: Survey Results on Four Important Issues. Journal of Rheumatic Diseases, 2013, 20, 156.	0.4	1
229	Long-term Safety and Efficacy of Abatacept in Koreans with Rheumatoid Arthritis. Journal of Rheumatic Diseases, 2013, 20, 30.	0.4	1
230	Development of rheumatoid arthritis specific HLA-DRB1 genotyping microarray. Biochip Journal, 2014, 8, 187-198.	2.5	1
231	Agreement of Major Diagnosis and Comorbidity between Self-reported Questionnaire and Medical Record Review in Patients with Rheumatic Disease. Journal of Rheumatic Diseases, 2016, 23, 348.	0.4	1
232	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	1.6	1
233	Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation for Refractory Rheumatic Diseases. Journal of Rheumatic Diseases, 2017, 24, 149.	0.4	1
234	Deletion at 2q14.3 is associated with worse response to TNF-Î± blockers in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 195.	1.6	1

#	Article	IF	Citations
235	High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis. Patient, 2019, 12, 319-326.	1.1	1
236	P210â€ƒEfficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results. Rheumatology, 2020, 59, .	0.9	1
237	Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus. Human Molecular Genetics, 2022, 31, 1082-1095.	1.4	1
238	CS-07â€…Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
239	Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values. International Journal of Rheumatic Diseases, 2019, 22, 852-859.	0.9	0
240	267â€…Relative expression strength of HLA-DRB1 in heterozygotes is associated with rheumatic diseases. , 2019, , .		0
241	AB1273â€…ESTABLISHMENT OF A PROSPECTIVE COHORT FOR RHEUMATOID ARTHRITIS PATIENTS WITH INTERSTITIAL LUNG DISEASE: COMPARISON OF BASELINE CHARACTERISTICS BETWEEN RHEUMATOID ARTHRITIS PATIENT WITH OR WITHOUT INTERSTITIAL LUNG DISEASE. , 2019, , .		0
242	52â€…Contact dynamics between mesenchymal stem cells and T cells in lupus-prone MRL/lpr mouse model. , 2019, , .		0
243	Cost-effectiveness of Early Use of Etanercept in the Treatment of Rheumatoid Arthritis. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2009, 17, 93.	0.1	0
244	Ulnar artery vasculopathy: a common but nonspecific feature of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 221-224.	1.0	0
245	1124â€…Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
246	1107â€…Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
247	801â€…Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk. , 2021, , .		0
248	1704â€…Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
249	Intractable Progressive Cerebral Infarction with Multiple Atypical Aneurysms in Systemic Lupus Erythematosus. Journal of Neurosonology and Neuroimaging, 2021, 13, 71-75.	0.0	0
250	Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis. Korean Journal of Internal Medicine, 2021, , .	0.7	0